文献速递创伤骨科骨质疏松与代谢性骨病

特立帕肽与利塞膦酸钠对股骨转子间骨折后恢复的影响:一项26周随机、阳性对照、双盲临床试验结果

Effects of Teriparatide Compared with Risedronate on Recovery After Pertrochanteric Hip Fracture: Results of a Randomized, Active-Controlled, Double-Blind Clinical Trial at 26 Weeks.
PubMed 文献 · J Bone Joint Surg Am · 2016-01-01

这项随机、多中心、阳性对照、双盲78周试验比较特立帕肽(20 μg/天)与利塞膦酸钠(35 mg/周)对低能量股骨转子间骨折固定后恢复的影响。26周时特立帕肽组完成计时起立行走测试时间更短、测试后即刻疼痛更轻,其他骨折恢复结局相似;作者提示结果需谨慎解读因这些为次要终点。

要点

  • 特立帕肽组在6、12、18、26周完成TUG测试时间均短于利塞膦酸钠组,总体差异p=0.021。
  • 特立帕肽组在12、18周TUG测试后即刻VAS疼痛评分低于利塞膦酸钠组(p<0.05)。
  • 两组SF-36评分、Charnley髋痛评分、行走能力、影像学愈合及植入物失败等无显著差异。

核心结论

  • 与利塞膦酸钠相比,特立帕肽与6至26周间疼痛更轻和完成TUG测试时间更短相关,其他骨折恢复结局相似。
  • 作者提示结果应谨慎解读,因为这些是次要终点。

研究设计与样本

  • 随机、多中心、阳性对照、双盲78周试验,比较特立帕肽(20 μg/天)与利塞膦酸钠(35 mg/周),在低能量股骨转子间骨折(AO/OTA 31-A1或31-A2)固定后2周内开始用药。
  • 主要纳入标准为骨密度T值≤-2.0且25-羟维生素D≥9.2 ng/mL;前26周患者双盲接受研究药物加口服或注射安慰剂以及钙和维生素D。
  • 224例患者随机化,171例(特立帕肽86例、利塞膦酸钠85例)纳入分析;平均年龄77±8岁,77%为女性,26%有低能量骨折史。

主要发现

  • 特立帕肽组在6、12、18、26周完成TUG测试时间较利塞膦酸钠组分别缩短5.7、4.4、3.1、3.1秒,总体差异p=0.021。
  • 特立帕肽组在12、18周TUG测试后即刻VAS疼痛评分较利塞膦酸钠组调整后绝对差异分别为10.6和11.9 mm(p<0.05)。
  • 两组SF-36评分、Charnley髋痛评分、行走能力及助行器使用在随访期间无显著组间差异。
  • 6、12、26周影像学愈合、植入物机械失败(特立帕肽7例 vs 利塞膦酸钠8例)、复位丢失(特立帕肽2例 vs 利塞膦酸钠4例)及骨不连(0例)无显著差异。
  • 轻度高钙血症和高尿酸血症在特立帕肽组更常见。

关键数值与推荐

  • 特立帕肽剂量20 μg/天,利塞膦酸钠35 mg/周,骨折固定后2周内开始。
  • 主要纳入标准:骨密度T值≤-2.0且25-羟维生素D≥9.2 ng/mL。
  • 证据等级:治疗性II级。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 作者提示结果应谨慎解读,因为这些是次要终点。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Osteoporosis drugs might affect fracture-healing. We therefore studied the effects of teriparatide in comparison with risedronate on recovery after pertrochanteric hip fractures. METHODS: The study was a randomized, multicenter, active-controlled, 78-week trial comparing teriparatide (20 μg/day) with risedronate (35 mg/week) initiated within 2 weeks after fixation of a low-trauma pertrochanteric hip fracture (AO/OTA 31-A1 or 31-A2). The main inclusion criteria were a bone mineral density T-score of ≤-2.0 and 25-OH-vitamin D of ≥9.2 ng/mL. During the first 26 weeks, patients received study medication with oral or injectable placebo plus calcium and vitamin D in a double-blinded fashion. Secondary (Timed Up-and-Go [TUG] test, hip pain, Short Form [SF]-36 health status, and safety) and exploratory (radiographic outcomes and ability to walk) 26-week end points are reported. RESULTS: Of the 224 patients who were randomized, 171 (86 teriparatide, 85 risedronate) were included in the analysis. The mean age was 77 ± 8 years, 77% were female, and 26% had a prior history of low-trauma fracture. The teriparatide group completed the TUG test in a shorter time at 6, 12, 18, and 26 weeks (differences of -5.7, -4.4, -3.1, and -3.1 seconds, respectively; p = 0.021 for the overall difference). They also reported less pain on a visual analog scale immediately after the TUG test at 12 and 18 weeks (adjusted absolute differences of 10.6 and 11.9 mm, respectively; p < 0.05). There were no significant between-group differences in the SF-36 score, Charnley hip pain score, ability to walk, or use of walking aids during follow-up. Radiographic healing at 6, 12, and 26 weeks, mechanical failure of the implant (teriparatide, 7; risedronate, 8), loss of reduction (teriparatide, 2; risedronate, 4), and nonunion (0 cases) were not significantly different. Mild hypercalcemia and hyperuricemia were more frequent with teriparatide. CONCLUSIONS: Teriparatide was associated with less pain and a shorter time to complete the TUG test between 6 and 26 weeks compared with risedronate. Other fracture-recovery outcomes were similar. The results should be interpreted with caution as these were secondary end points. LEVEL OF EVIDENCE: Therapeutic Level II. See Instructions for Authors for a complete description of levels of evidence.

来源:J Bone Joint Surg Am,查看原文。版权归原作者所有。

引用

  1. Aspenberg P, Malouf J, Tarantino U, et al. Effects of Teriparatide Compared with Risedronate on Recovery After Pertrochanteric Hip Fracture: Results of a Randomized, Active-Controlled, Double-Blind Clinical Trial at 26 Weeks. J Bone Joint Surg Am. 2016. PMID: 27852903

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。